Research map: Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial)

Back to the article

Papers in this map

  1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection · Pietro Lampertico · 2017 · 5529 citations · Cited by this paper
  2. Stopping is only the beginning: Sequential immune therapy after nucleos(t)ide analog withdrawal in chronic hepatitis B · Markus Cornberg · 2026 · Cites this paper
  3. AASLD-EASL Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis · 2026 · Related
  4. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 · Aparna Schweitzer · 2015 · 2807 citations · Cited by this paper
  5. Bile acids as the silent harbinger: Early signals of portal hypertension after “successful” Kasai · 2026 · Related
  6. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B · Patrick Marcellin · 2004 · 1149 citations · Cited by this paper
  7. Context-dependent STAT3 signaling in liver fibrosis · 2026 · Related
  8. Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir · Stephanos J. Hadziyannis · 2012 · 350 citations · Cited by this paper
  9. Buying time: Therapeutic plasma exchange as a bridge to transplant in acute-on-chronic liver failure · 2026 · Related
  10. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study · Thomas Berg · 2017 · 320 citations · Cited by this paper
  11. Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial · 2026 · Related
  12. Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a · Patrick Marcellin · 2009 · 316 citations · Cited by this paper
  13. Two decades of hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions · 2026 · Related
  14. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review · George Papatheodoridis · 2016 · 281 citations · Cited by this paper
  15. H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis · 2026 · Related
  16. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B · Christoph Höner zu Siederdissen · 2016 · 143 citations · Cited by this paper
  17. Diabetes, male sex, low levels of HBsAg, HDV RNA, and ALT predict spontaneous HDV suppression in chronic hepatitis D · 2026 · Related
  18. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B · Franziska Rinker · 2018 · 142 citations · Cited by this paper
  19. AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation · 2026 · Related
  20. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial · Marc Bourlière · 2017 · 121 citations · Cited by this paper
  21. Seeing the scar in higher resolution: AI-derived collagen phenotypes redefine fibrosis in MASLD · 2026 · Related
  22. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B · Pietro Lampertico · 2012 · 118 citations · Cited by this paper
  23. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT · Seng Gee Lim · 2021 · 49 citations · Cited by this paper
  24. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B · Florian van Bömmel · 2021 · 41 citations · Cited by this paper
  25. Current State of Interferon Therapy in the Treatment of Chronic Hepatitis B · Michael Peter Manns · 2002 · 36 citations · Cited by this paper
  26. PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial · Fahong Li · 2024 · 26 citations · Cited by this paper
  27. Increasing functional cure rates after nucleo(s)tide analogue withdrawal: Is peg-IFN the answer? · Edo J. Dongelmans · 2024 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)